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ABSTRACT 
Objectives: The number of systematic reviews that aim to compare multiple interventions using 
network meta-analysis is increasing. In this paper, we highlight aspects of a standard systematic 
review protocol that may need modification when multiple interventions are to be compared.  
Study Design and setting: We take the protocol format suggested by Cochrane for a standard 
systematic review as our reference, and compare the considerations for a pairwise review with those 
required for a valid comparison of multiple interventions. We suggest new sections for protocols of 
systematic reviews including network meta-analyses with a focus on how to evaluate their 
assumptions. We provide example text from published protocols to exemplify the considerations.  
Results and Conclusion: Standard systematic review protocols for pairwise meta-analyses need 
extensions to accommodate the increased complexity of network meta-analysis. Our suggested 
modifications are widely applicable to both Cochrane and non-Cochrane systematic reviews 
involving network meta-analyses. 
 
Keywords: comparative effectiveness review; eligibility criteria; transitivity; network meta-analysis; 
indirect comparison; mixed treatment comparison  
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What is new? 
 
• The standard format of systematic review protocols can be extended for a comparative 
effectiveness systematic review that aims to compare three or more interventions 
• Consideration of the underlying assumptions of network meta-analysis is important when 
planning a comparative effectiveness systematic review to ensure a consistent evidence base  
• Systematic reviewers and journal editors should consider the suggestions herein and publish 
protocols that include methodological considerations pertinent to comparative effectiveness 
systematic reviews and network meta-analyses  
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1 Introduction 
The number of systematic reviews that simultaneously compare multiple interventions surges in the 
medical literature (1,2). Such reviews, which we refer to as comparative effectiveness reviews 
(CER), may include a data synthesis component, network meta-analysis (NMA). The popularity of 
the technique prompted the rapid methodological development of NMA, the availability of technical 
guidance, statistical tutorials (3–7), and recommendations for the proper conduct and reporting of 
CER (8–12). Good practice requirements of a standard systematic review apply equally to a CER, 
although several practices need to be adapted to accommodate the complexity imposed by comparing 
more than two interventions at a time.  
A protocol for a systematic review provides a pre-specified outline of the research question under 
consideration as well as the detailed methods of the review (13). Review authors are encouraged to 
register the protocol using an international repository such as PROSPERO (14) to ensure 
transparency and reproducibility. As a key player in producing high-quality systematic reviews, 
Cochrane requires publication of the review protocol following an established methodology and 
outline (13).  
In this paper, we aim to highlight parts of a protocol for a systematic review that may need special 
consideration when three or more competing interventions are to be compared. The protocol items 
that generally do not need modifications include the background, search strategy, the definition of 
the outcomes of interest and the risk of bias assessment for the included studies. Most items, though, 
require modifications. We organize our guidance following the protocol format suggested by 
Cochrane for a standard systematic review and elaborate on sections that need adjustment to address 
methodological issues pertinent to CER and NMA. We have previously prepared a protocol template 
for Cochrane authors (available on the website of the Cochrane Comparing Multiple Interventions 
Group http://methods.cochrane.org/cmi/) (15). Following feedback from users of this template, we 
elaborate on our previous work accordingly. The present paper replaces the template and aims to 
disseminate our recommendations to the wider community of systematic reviewers. We assume that 
readers are familiar with the basic requirements and statistical methods underpinning NMA, and 
direct interested readers to published tutorials for further guidance (16,17). Throughout we provide 
example text from published protocols to exemplify the considerations.  
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2 Illustrative CER protocols 
We use three published CER protocols including NMA as our examples: (1) comparative 
effectiveness and safety of different treatments for panic disorder in adults (18); (2) safety of anti-
epileptic drugs (AEDs) on infants and children exposed in utero or during breastfeeding (19); and (3) 
efficacy and acceptability of first- and second-generation antidepressants in the acute treatment of 
major depression (20).  
 
3 Sections of a CER protocol and considerations for NMA 
3.1 Setting the rationale for the review: background and objectives 
Systematic reviews are intended to summarize evidence to inform decision-making. In any protocol 
for a systematic review on the effects of interventions, authors should describe the rationale for the 
review. In the background section of CER protocols, authors should specify their rationale for 
undertaking a CER and justify their intention to use NMA (9). The presence of several competing 
interventions and multiple independent pairwise comparisons may persuade researchers to synthesize 
simultaneously all the available data via NMA, so that the comparative effectiveness and safety of all 
possible comparisons between pairs of interventions can be estimated (21,22). In the absence of 
head-to-head trials comparing the active interventions of interest directly, when direct comparisons 
are limited, or when the aim is to assess the relative ranking of interventions across a range of 
clinical outcomes, a CER using NMA is the best available approach (17). However, as NMA rests on 
assumptions that can be difficult to evaluate, researchers should clarify which review questions are 
best achieved using NMA.  
Review authors should also define in their objectives the health condition, population(s), setting(s), 
interventions, and outcome(s) of interest (13). The main difference for a NMA is that the list of 
interventions of interest is likely to be longer, and the distinction between interventions and 
comparators is not obvious: an intervention might be used as the experimental treatment in one study 
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and the control comparator in another. Hence, “IC” in the PICO acronym should be interpreted as a 
list of all the interventions to be compared. 
For example, in the anti-epileptics protocol the authors justified the need for their review by stating 
that (19): “Some AEDs have been associated with increased risk of harm to the fetus and infants. For 
example, exposure to valproate has led to increased risk of major congenital malformations (23), 
cognitive delay, and minor congenital abnormalities (24–27). Phenobarbital has been associated 
with minor congenital abnormalities and developmental delay (23,28). Carbamazepine and 
lamotrigine have been associated with minor congenital abnormalities (29–32). However, other than 
studies of the use of valproate, many studies have produced inconsistent findings regarding harm to 
the fetus and infant with use of other agents (33). As such, our objective is to evaluate the 
comparative safety of AEDs for infants and children who were exposed in utero or during 
breastfeeding through a systematic review and network meta-analysis” 
3.2 Specifying the eligibility criteria and the network of possible comparisons 
A review protocol will specify the eligibility criteria for studies and participants in light of the 
research question and the risk of important heterogeneity. This means that eligible studies should be 
similar enough in terms of design and participant characteristics to ensure a sufficiently 
homogeneous evidence base that can be validly synthesized. For a standard systematic review, the 
eligible interventions are defined by describing the pairwise comparison(s) of interest, such as the 
comparison of a new treatment versus an existing intervention.  
In a CER with NMA, the eligibility criteria should clearly consider the transitivity (or 
exchangeability) assumption (21,22). This requires sufficient clinical and methodological 
comparability across all direct comparisons in the whole network. It implies that one can validly 
compare two interventions via a connected indirect route involving one or more intermediate 
comparators (21,22). When defining the population and interventions of interest the review author 
should assess the plausibility of this assumption, which requires all included interventions to be 
legitimate alternatives and therefore considered jointly randomizable. Joint randomizability means 
that a large multi-arm trial including all eligible interventions is conceptually meaningful even if 
practically not feasible (22). Authors should state in the protocol whether they believe that this might 
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be a reasonable setting for the expected network of interventions, for instance, by reporting that “We 
assume that patients who fulfil the inclusion criteria are equally eligible to be randomised to any of 
the interventions we plan to compare”. If such an assumption is not likely to hold a priori, it might 
be necessary to set narrower eligibility criteria for included interventions and populations. More 
extensive discussions on the plausibility of transitivity and examples of situations where this 
assumption might be violated can be found elsewhere (17,34,35). 
Another difference between a standard systematic review protocol and a CER with NMA protocol is 
that review authors may distinguish between interventions of direct interest for forming 
recommendations for practice (also called the decision comparator set (12)) and interventions 
included to supplement the analysis. Additional interventions (such as placebo or no treatment) may 
provide useful information for the treatments of interest via indirect evidence. These additional 
interventions are expected to increase the precision of the results (36), connect a sparse network or 
help estimate heterogeneity, among other reasons. The concept of joint randomizability should apply 
to all treatments included in the network. In other words, an individual should be eligible to be 
allocated to any of the available interventions irrespective of whether it is of direct interest or 
supplementary. As there may be a diminishing return of including supplemental interventions in an 
analysis (35), a CER protocol should provide rationale for including them. The synthesis set cannot 
always be specified a priori, because the authors of the review may not be aware of all eligible 
interventions. Thus the protocol should also include information on whether unspecified 
interventions will be considered for post-hoc inclusion in the network within the context of jointly 
randomizable interventions, and how such decisions will be made. 
Different eligibility criteria for interventions will result in different collections of evidence in the 
synthesis, and due to the interrelationships across direct and indirect evidence this can lead to 
different effect estimates and relative rankings (37). Restrictions to eligibility should be given a clear 
rationale. A graphical illustration of the anticipated network of competing interventions is highly 
desirable to present, in a comprehensive way, the definition of the nodes in the network and present 
any intended grouping or splitting of interventions as part of secondary analyses (e.g. by 
distinguishing different dosages of the same drug) (38). In the depression example, the authors list 21 
drugs and placebo as eligible interventions and then they explain why they selected this set of 
interventions (20).  
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Finally, in this section the authors could describe how they plan to deal with different intervention 
doses, modalities, administration frequencies and routes as well as with co-interventions (39–41). 
Interventions should be fully described to the extent possible. Review authors sometimes split the 
nodes of the network to be able to explore differences within intervention nodes. It is possible, 
though, that they will eventually follow a lumping approach due to limited availability of data to 
explore such differences. To date no unanimously optimal approach has been suggested to define the 
nodes of the network as this depends on the clinical context. A decision on lumping or splitting the 
nodes of a network should be formed on the basis of the research question of the review and the 
outcomes of interest, as well as considering the underlying assumptions (i.e. merging insufficiently 
similar interventions might violate transitivity).       
In the depression network, the authors addressed the issue of the different drug doses in their 
inclusion criteria and considering a sensitivity analysis (20): “We will include only study arms 
randomising patients to drugs within the licensed dose. Both fixed-dose flexible-dose designs will be 
allowed (42). There is a possibility that some trials compare one agent at the upper limit of its 
therapeutic range with another agent at the lower limit of its therapeutic range within the same 
study. We plan to capture this study characteristic by adding a dichotomous variable indicating 
whether dosages are comparable, and use this information for a sensitivity analysis.”.  
3.3 Specifying the outcomes of interest 
A systematic review protocol should define a priori all primary and secondary outcomes of interest 
(43). It also should explain the preferred ways of measuring, aggregating, and analyzing outcomes to 
reduce the risk of selective inclusion of outcomes and results on the part of the systematic reviewer. 
However, it is common in CERs to perform NMA only for a subset of the pre-specified outcomes, 
due to lack of data. Review authors should be aware that in a CER different interventions may work 
with different mechanisms across multiple time points, and therefore combining outcomes measured 
at different follow-up times might be inappropriate. In addition, different interventions might lead to 
different adverse events and therefore review authors should focus on adverse outcomes that are 
potentially relevant to all or at least most of the interventions. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
9 
 
The reporting of the outcomes under investigation should not be considered as a criterion for 
including studies. The number and size of studies that do not report the outcome of interest will be 
considered when interpreting the summary estimates. It is possible that unreported outcomes are not 
favourable for the studied interventions, and therefore the summary estimate would have been 
different had these missing outcomes being observed. CER protocols should mention that network 
diagrams will be produced to show the amount of evidence and the topology for all selected studies 
and for each subset of studies contributing to each outcome. 
It is also recommended that in this section of the protocol authors should specify for which 
outcomes, if at all, the authors plan to estimate the relative ranking of the competing interventions. 
For example, the protocol of the depression network reports (20): “[…] we will conduct a random 
effects NMA to synthesise all evidence for each outcome, and obtain a comprehensive ranking of all 
treatments.”. 
3.4 Searching and selecting eligible studies 
A detailed description of the intended search strategy and selection process should be included in any 
systematic review protocol to ensure that authors will make the best effort to identify all potentially 
eligible studies for the review. In NMA, all studies comparing at least two of the competing 
interventions in the synthesis set are eligible for inclusion. Hawkins et al. (44) have suggested 
methodology for building iterative search algorithms with the aim of identifying studies that may 
provide useful indirect evidence. Constructing the evidence base for a CER with NMA is usually a 
complex procedure. Involvement of a knowledgeable librarian is recommended. 
3.5 Describing the data extraction process and risk of bias assessment 
In general, a protocol will specify the information that review authors plan to extract from the 
included studies. For example, this may include study design and setting, studied population, dosage 
of interventions, outcome data, and risk of bias assessments (45). For standard systematic reviews, 
the extraction of study or patient characteristics that potentially act as effect modifiers is usually 
associated with subgroup analyses or meta-regression for the investigation of heterogeneity. The 
strategy to compute missing statistics (such as standard deviations) is often described. Risk of bias 
assessments for NMAs will typically be similar to those for standard systematic reviews. However, it 
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is possible that different judgements might be made about risks of bias for different pair-wise 
comparisons within a multi-arm trial. 
Similar to standard systematic review protocols, a CER protocol including NMA requires to specify 
whether arm-level or contrast-level (i.e. effect sizes and standard errors comparing a pair of 
interventions) data will be extracted when both are available, since this has implications for the 
choice of statistical model. Also, in a NMA the impact of potential effect modifiers needs to be 
evaluated in the context of the transitivity assumption. The plausibility of transitivity can be judged 
by comparing the distribution of the potential effect modifiers across the available direct 
comparisons in the network (10,22,46). Therefore, data extraction on these characteristics is 
necessary rather than optional. Authors should also describe how these could be related to the 
violation of the transitivity assumption. 
For example, in the panic disorder protocol the authors report (18): “From each included study we 
will extract data on the following study, interventions and population characteristics that may act as 
effect modifiers: 
1. Methods: study design, randomization (individual or cluster), total duration of study, number of 
study centres and location, study setting, withdrawals, and date of study. 
2. Participants: number, setting, diagnostic criteria, presence or absence of medical and 
psychiatric comorbidities, presence or absence of elderly participants, percentage of patients 
with agoraphobia, percentage of patients with baseline depression, inclusion criteria, and 
exclusion criteria. 
3. Interventions: medication dose, medication dose range, use of rescue medication. 
4. Outcomes: primary and secondary outcomes specified and collected, and time points reported. 
Where possible we will extract data at the arm level, not summary effects. 
5. Notes: sponsorship/funding for trial, and notable conflicts of interest of trial authors” 
3.6 Selecting effect measures 
Every protocol should report the effect measure(s) the authors intend to use for each outcome of 
interest. It should specify both the effect measures to be used in the statistical analyses and the effect 
measures to be used in the presentation of the findings, as these will not necessarily be the same. For 
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example, ratio scales are often preferred to analyse the data as they are associated with better 
mathematic properties, but presentation of results using absolute measures (such as the risk 
difference) is desirable as these measures are easier to interpret. Also, the use of multiple effect 
measures should be justified and the way any discrepancies between them will be handled should be 
described. 
The additional consideration for a CER with NMA protocol is whether authors will also report the 
relative ranking of the competing interventions for one or more of the outcomes. This relates to the 
aims of the CER; they often include statements like “we will obtain a comprehensive ranking of all 
treatments” (from the depression protocol (20)). In such cases, unlike standard systematic review 
protocols, protocols including NMA should specify a priori the measure that will be used to rank the 
competing interventions (e.g. cumulative ranking curves, SUCRAs, mean ranks, or median ranks) as 
well as how the uncertainty of ranking will be reflected in the conclusions (47,48). For example, 
graphical tools such as the rankograms reflect visually the uncertainty in the ranking probabilities 
(38,49,50). Reviewers should refrain from using the probabilities of being the best as a measure of 
relative ranking because these are known to yield misleading intervention hierarchies (51). 
In the panic disorder CER protocol the authors considered the following measures for relative 
ranking (18): “We will also estimate the ranking probabilities for all treatments of being at each 
possible rank. We will also obtain a treatment hierarchy using the surface under the cumulative 
ranking curve (SUCRA) and mean ranks (49). SUCRA can also be re-expressed as a percentage 
interpreted as the percentage of effectiveness/acceptability of an intervention that would be ranked 
first without uncertainty.”  
3.7 Unit of analysis issues and missing outcome data 
Protocols should explicitly describe how authors plan to deal with cluster-randomized and crossover 
trials. Ignoring the different design of such studies in the analysis can yield biased findings or 
findings with inappropriate precision. NMAs are also subject to the same biases that may arise when 
special study designs or missing data are treated incorrectly.  
An additional threat to the validity of results is the presence of missing data. Authors should describe 
their strategy for obtaining missing information as well as any methods they will use, and the 
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underlying assumptions made, in studies with missing data in the analysis. When missing outcome 
data are believed to be an important threat to the validity of study results, the amount of and reasons 
for missingness need to be considered when drawing conclusions about the risk of attrition bias and 
the robustness of the inference. While the same considerations are applicable to CER, making 
assumptions about how informative is missingness become increasingly complex as one needs to 
consider the reasons for missingness in each intervention arm. For more information about the 
methodology on this issue the reader may consult elsewhere (52,53).  
3.8 Qualitative assessment of the appropriateness of a synthesis  
The underlying assumption in a standard meta-analysis is that studies evaluating the same 
comparison have enough clinical and methodological similarities to make their synthesis meaningful. 
This assumption refers to the comparability/similarity in terms of population characteristics as well 
as study design, intervention, outcomes and settings (54). In a standard systematic review protocol, 
authors should state how they plan to examine this assumption, for example by generating 
descriptive statistics to assess whether characteristics are comparable across all studies that inform a 
pairwise comparison. 
The same ideas translate to the whole network of studies in a NMA. The validity of NMA relies on 
the transitivity assumption. As discussed above, the assumption of transitivity can be assessed by 
comparing the distribution of the potential effect modifiers across the direct comparisons in the 
network (10,46). However, the utility of this approach is sometimes limited by the fact that effect 
modifiers are under-reported, or that very few studies are available for each direct comparison. A 
strategy for assessing both clinical and methodological homogeneity and transitivity should be 
considered. 
In the depression example the authors plan to evaluate transitivity using the following approach (20): 
“The clinical features, which have been demonstrated to date to moderate efficacy of antidepressants 
include bipolarity (55),  psychotic features (56), and subthreshold depression (57).  We have assured 
transitivity in our network with regard to these variables by limiting our samples to participants with 
non-psychotic unipolar major depression. Other clinical or methodological variables that may 
influence our primary outcomes of antidepressant efficacy or acceptability include: age, depressive 
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severity at baseline (58,59),  and the dosing schedule (60).  We will investigate if these variables are 
similarly distributed across studies grouped by comparison. The inclusion of placebo and concerns 
about its potential to violate the transitivity assumption have been highlighted in general (17,61)  
and particularly in depression studies (62,63). Consequently, the comparability of placebo-
controlled studies with those that provide head-to-head evidence will be examined carefully.”  
3.9 Describing the planned statistical analyses 
CERs can involve two types of analyses: a series of independent pairwise meta-analyses and NMA. 
Review authors should state in the protocol whether they intend to use both analyses. Additionally, 
as in standard systematic review protocols, the description of the planned statistical analysis should 
include technical details of the statistical model and a justification for model choice.  
Authors should report the specific statistical model they will use to fit NMA (e.g. as multivariate 
meta-analysis (64) or a hierarchical model (3,65)). It is highly recommended to specify the 
framework (Bayesian vs frequentist) and the software to be used for analysis. If a Bayesian 
framework is to be used, additional technical details such as prior distributions and convergence of 
Markov chain Monte Carlo approaches should be described. Finally, assumptions about the 
heterogeneity variance and the method for estimating it should be reported; specifically whether a 
single heterogeneity parameter will be assumed for all comparisons or different, comparison-specific 
parameters will be employed. Reviewers should also report whether the method they plan to use to 
synthesize data correctly accounts for the correlated nature of data from multi-arm studies (66). The 
complexity of the methodology makes the involvement of a knowledgeable statistician with 
experience in NMA critical. 
For example, in the depression protocol both direct meta-analyses and NMA are described (20): 
“For each pair-wise comparison, we will synthesise data to obtain summary standardised mean 
differences (SMD, Cohen’ s d) for continuous outcomes or ORs for dichotomous outcomes, both with 
95% Credible Intervals (CrI). […] If the collected studies appear to be sufficiently similar with 
respect to the distribution of effect modifiers (refer Assessment of transitivity assumption section), we 
will conduct a random effects NMA to synthesise all evidence for each outcome, and obtain a 
comprehensive ranking of all treatments.[…]” 
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In a standard systematic review protocol, authors should describe the methods they plan to use for 
the evaluation of statistical heterogeneity (e.g. via a chi-squared test or the  measure) if they expect 
to synthesize a set of comparable studies.  
There are statistical means to examine heterogeneity in a NMA, such as an I-square, and the estimate 
of the common heterogeneity variance (6,67,68). Protocols including NMA should describe the 
intended strategy to infer about statistical inconsistency which, when present, reflects the risk of 
important intransitivity. The different available methods are often classified into local and global 
approaches (68). Local approaches (e.g. contrasting direct evidence with indirect from a specific loop 
(termed loop-specific approach (69)) or with indirect from the entire network (termed node-splitting 
(70)) aim to identify pairwise comparisons or loops of evidence that might introduce important 
inconsistency in the network. Global approaches (e.g. inconsistency models (71,72)) assess the 
potential for inconsistency in the entire network. Each approach may lead to different conclusions 
with respect to the presence or the magnitude of inconsistency and thus the use of both local and 
global approaches is highly recommended (73).  
In the anti-epileptic drugs example the authors consider the following approaches for evaluating 
inconsistency (19): “We will ensure the following factors are present prior to conducting network 
meta-analysis: […] ii) consistency between direct and indirect data, which will be examined locally 
(i.e., in certain paths of the network) using the loop-specific method (74,75) and the node-splitting 
method (70), and globally (i.e., evaluating the network as a whole), using the design-by-treatment 
interaction model (72); and iii) we will quantify the amount of variability attributed to heterogeneity 
and inconsistency rather than sampling error, by calculating the I2 (67). […] We will compare the 
magnitude of heterogeneity between consistency and inconsistency models to determine how much 
heterogeneity will be explained by inconsistency. We will first use the design-by-treatment model for 
the evaluation of inconsistency in a network as a whole and then, if inconsistency is detected, we will 
employ the loop-specific and node-splitting methods to identify which piece of evidence is 
responsible for inconsistency”.  
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3.10 Assessing reporting biases 
Reporting biases, such as publication bias and selective outcome reporting bias, can occur in 
systematic review even after a well-designed and comprehensive search strategy. To assess the 
impact of possible reporting biases in standard systematic review, protocols usually consider the use 
of methods for small-study effects (funnel plots, Egger’s test, etc.) (76) and rarely more sophisticated 
methods such as selection models (77). 
These approaches have been extended to the context of NMA (38,78–80) and should be considered 
when drafting the respective section of a CER protocol. In particular, the comparison-adjusted funnel 
plot is an extension of the conventional graph that accounts for the fact that different studies estimate 
different effects (38,80). However, their application often requires additional assumptions for the 
direction of potential bias particularly when head-to-head comparisons of active interventions are 
included in the network. Review authors should, when possible, describe in their protocol the 
assumptions they will make about reporting biases and the rationale behind these choices. 
For example, the depression protocol (20) reports: “We will use the comparison-adjusted (38)  and 
contour-enhanced (81) funnel plots to investigate whether results in imprecise trials differ from those 
in more precise trials. We will also run network meta-regression models to detect associations 
between study size and effect size (80).  If an important association is found and publication bias is 
suspected, we will attempt to explore the possibility that funnel plot asymmetry is due to publication 
bias by employing a selection model (82). ”. The authors here should have ideally also pre-specified 
the assumptions about the direction of small-study effects within the network. 
3.11 Investigating heterogeneity and inconsistency 
Heterogeneity and inconsistency are caused by differences in populations or other study 
characteristics that modify the intervention effects within and across comparisons respectively (83). 
These characteristics may be included in the list of known potential effect modifiers or might be 
other unknown factors.  
Standard systematic review protocols describe any additional analyses the authors plan to perform to 
explain anticipated heterogeneity in the data. Similarly in protocols including NMA researchers 
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should report which characteristics they consider as possible sources of heterogeneity and 
inconsistency. The impact of such characteristics on the relative effects may be explored via pre-
specified subgroup or meta-regression analyses. Interpreting subgroup analyses in NMA might be 
challenging since subgroups of studies can lead to exclusion of interventions; in such case a 
comparison of the results between the different subgroups or with the primary analysis can be 
inappropriate (37).  
When network meta-regression analysis is planned, further detail might be necessary regarding the 
assumptions related to the estimation of the regression coefficients (e.g. assuming consistency or not 
across coefficients) (84) and the directionality of the effect of covariates. For example, when 
controlling for risk of bias items in a full network of interventions, the direction of bias is 
straightforward in placebo-controlled trials (active treatments are expected to be favored) but not in 
head-to-head trials where stronger assumptions might be necessary (e.g. assuming that newer 
treatments are favored) (80). If the meta-regression model will be fitted in a Bayesian framework, 
information on the prior distributions for the regression coefficients should also be given. Finally, 
review authors also may pre-specify sensitivity analyses to investigate the robustness of findings to 
particular choices of statistical or non-statistical approach to the NMA. 
In the depression network the authors suggest six possible sources of non-random variation (20): 
“We will explore whether treatment effects for the two primary outcomes are robust in subgroup 
analyses and network meta-regression using the following characteristics: (1) study year; (2) 
sponsorship; (3) depressive severity at baseline; (4) dosing schedule; (5) response to placebo; (6) 
proportion of participants allocated to placebo; number of recruiting centres (single-centre vs 
multicentric studies) (85,86). ”. 
3.12 Credibility of the evidence and summary of findings table 
The most commonly used system to evaluate the credibility of the evidence in a standard systematic 
review is the Grade of Recommendation, Assessment, Development and Evaluation (GRADE) 
system, which considers that our confidence to the available evidence might be downgraded with 
respect to five domains (study limitations, indirectness, inconsistency, imprecision, publication bias) 
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(87). Typically, the ratings according to GRADE along with the intervention effects for the most 
important outcomes of the systematic review are presented in a summary of findings table. 
Two approaches extending the GRADE system into NMA are currently available and can be 
considered when preparing a protocol for a CER including NMA (68,88). For large networks, it 
might be challenging to present the credibility of evidence for every comparison. Therefore, a 
selected set of the most important comparisons and outcomes should be defined in the protocol for 
inclusion in the summary of findings table. The full table and the GRADE judgements could be 
presented in an appendix.    
 
4 Conclusions 
The most important considerations for CER protocols are summarised in a Box.  As in the case of 
conventional systematic review, deviations from the protocol may occur in the final review. This 
phenomenon might be common in the conduct of CERs as decisions about NMA are particularly 
dependent on the data. Specifically, deviations from the protocol are often required due to data 
availability and the subsequent trade-offs that are needed between precision and connectedness on 
the one hand and adequate discrimination of interventions on the other. In this situation the authors 
should provide a clear description of the reasons that imposed making changes to the initial design of 
their review (13).  In conclusion, we urge review authors of NMA to prepare and share their 
protocols to minimize post-hoc decisions and to promote the culture of open science. We believe the 
guidance offered in this tutorial is widely applicable and is likely to improve the quality of NMA.  
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Box. Important considerations for comparative effectiveness review protocols with network meta-
analysis  in comparison with standard systematic review protocols
 
 
• Review authors should describe early on in the protocol the reasons that suggest a) the need and b) the 
appropriateness of a comparative effectiveness review with network meta-analysis in relation to the 
research question (e.g. absence or scarcity of direct evidence, obtaining a treatment hierarchy). 
• Inclusion criteria for studies, participants, and interventions should be defined in the light of 
transitivity. 
• Eligible interventions can be categorized into interventions of direct interest for recommendations for 
practice and interventions that provide indirect evidence (e.g. legacy treatments, placebo etc). 
Although the latter cannot always be pre-specified in the protocol, authors should give a clear 
rationale for their selection of interventions in both groups. 
• All potential effect modifiers need to be defined in comparative effectiveness review protocols as data 
on such characteristics are necessary for the evaluation of transitivity. 
• Measures for relative ranking should be specified in addition to relative effect measures. 
• Search strategy and study selection process should be designed such that any study that compares at 
least two of the eligible interventions and meets all other inclusion criteria be included in the network. 
• Authors should report the approach to network meta-analysis (e.g. multivariate meta-analysis, 
hierarchical model) they will use and any assumptions they make about heterogeneity variances.  
• A clear strategy for the assessment of statistical inconsistency should be given in every comparative 
effectiveness review with network meta-analysis protocol. 
• Methods to assess potential reporting biases for comparative effectiveness reviews with network meta-
analysis have been developed and should be considered in the protocol. 
• Possible sources of important heterogeneity and inconsistency should be specified in the protocol and 
used, if possible, in additional analyses to explore the impact of these variables on the findings. 
